TABLE 2.
Univariate and multivariate analysis of overall survival by involved sites between the non‐ASCT and ASCT groups.
| Univariate analysis | ||||
|---|---|---|---|---|
| Variable | Non‐ASCT | ASCT | ||
| HR, 95% CI | p | HR, 95% CI | p | |
| GCB vs. non‐GCB | 0.45 (0.15, 1.33) | 0.147 | 0.52 (0.06, 4.69) | 0.562 |
| IPI score high–intermediate or high versus the other | 1.05 (0.41, 2.71) | 0.924 | 0.38 (0.04, 3.37) | 0.383 |
| Interim PET Deauville score 3 or 4 versus 1 or 2 | 1.48 (0.57, 3.86) | 0.424 | 0.47 (0.05, 4.24) | 0.504 |
| EOT PET Deauville score 3 versus 1 or 2 | 4.61 (1.52, 14.0) | 0.007 | 2.02 (0.23, 18.2) | 0.529 |
| SUVmax > 18 versus ≤ 18 | 1.29 (0.52, 3.21) | 0.578 | 0.37 (0.04, 3.32) | 0.375 |
| Bulky disease ≥ 7.5 versus < 7.5 cm | 0.31 (0.07, 1.35) | 0.119 | 0.49 (0.05, 4.35) | 0.518 |
| Spleen involvement versus noninvolvement | 3.43 (1.44, 8.19) | 0.005 | 0.64 (0.07, 5.78) | 0.695 |
| Bone marrow involvement versus noninvolvement | 2.45 (1.04, 5.78) | 0.041 | 1.95 (0.32, 11.7) | 0.467 |
| Nasosinusal involvement versus noninvolvement | 2.31 (0.95, 5.57) | 0.063 | 9.55 (1.06, 85.6) | 0.044 |
| Mediastinum involvement versus noninvolvement | 1.24 (0.50, 3.08) | 0.641 | 3.57 (0.59, 21.4) | 0.164 |
| Lung or pleura involvement versus noninvolvement | 1.75 (0.68, 4.52) | 0.247 | 1.39 (0.16, 12.5) | 0.767 |
| Liver involvement versus noninvolvement | 2.28 (0.76, 6.80) | 0.14 | 13.5 (1.19, 154) | 0.036 |
| Gastrointestinal involvement versus noninvolvement | 0.49 (0.18, 1.33) | 0.16 | 1.04 (0.17, 6.21) | 0.968 |
| Breast involvement versus noninvolvement | NR (0.00, Inf) | 0.998 | NR (0.00, Inf) | 0.999 |
| Kidney or adrenal gland involvement versus noninvolvement | 0.79 (0.11, 5.88) | 0.816 | 1.01 (0.11, 9.05) | 0.993 |
| Genital involvement versus noninvolvement | 1.04 (0.24, 4.46) | 0.961 | 2.02 (0.23, 18.2) | 0.529 |
| Axial bone involvement versus noninvolvement | 1.61 (0.66, 3.91) | 0.291 | 0.47 (0.05, 4.24) | 0.504 |
| Skin or muscle involvement versus noninvolvement | 1.68 (0.61, 4.63) | 0.316 | 1.4 (0.23, 8.41) | 0.711 |
| Multivariate analysis | ||||
|---|---|---|---|---|
| Non‐ASCT | ASCT | |||
| EOT PET Deauville score 3 versus 1 or 2 | 5.47 (1.68, 17.8) | 0.005 | ||
| Spleen involvement versus noninvolvement | 4.19 (1.65, 10.6) | 0.003 | ||
| Bone marrow involvement versus noninvolvement | 2.16 (0.90, 5.20) | 0.084 | ||
| Nasosinusal involvement versus noninvolvement | 3 (1.18, 7.59) | 0.02 | 7.76 (0.81, 74.7) | 0.076 |
| Liver involvement versus noninvolvement | 5.15 (0.43, 62.1) | |||
Abbreviations: ASCT, autologous hematopoietic stem cell transplantation; CI, confidence interval; EOT, end‐of‐treatment; GCB, germinal center B‐cell‐like; HR, hazard ratio; IPI, International Prognostic Index; NR, not reached; P, p‐value; PET, positron emission tomography‐computed tomography; SUV, standardized uptake value.